Subcutaneous epcoritamab in combination with r (2) (Rituximab and Lenalidomide) in patients with relapsed or refractory follicular lymphoma: preliminary results from a Phase 1/2 Trial
Wahlin, B. Leepa, S. Morschhauser, F. Elliot, B. Liu, T. Stirner, M. C. Abbas, A. Falchi, L.
Wahlin, B.
Leepa, S.
Morschhauser, F.
Elliot, B.
Liu, T.
Stirner, M. C.
Abbas, A.
Falchi, L.
Citations
Altmetric:
Abstract
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Linton KM, Wahlin B, Leepa S, Morschhauser F, Elliot B, Liu T, et al. Subcutaneous Epcoritamab in Combination with R (2) (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736413906102.